Secchi, O., Franchi, A., & Lunello, A. (2023). Comments to “Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy”. AboutOpen, 10(1), 82–86. https://doi.org/10.33393/ao.2023.2600